Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-16-010659
Filing Date
2016-12-30
Accepted
2016-12-30 09:01:18
Documents
48
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 6-K sbbp-20160630x6k.htm 6-K 1241917
  Complete submission text file 0001558370-16-010659.txt   4363275

Data Files

Seq Description Document Type Size
2 EX-101.INS sbbp-20160630.xml EX-101.INS 808503
3 EX-101.SCH sbbp-20160630.xsd EX-101.SCH 37311
4 EX-101.CAL sbbp-20160630_cal.xml EX-101.CAL 38637
5 EX-101.DEF sbbp-20160630_def.xml EX-101.DEF 127196
6 EX-101.LAB sbbp-20160630_lab.xml EX-101.LAB 364212
7 EX-101.PRE sbbp-20160630_pre.xml EX-101.PRE 244353
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

EIN.: 981130690 | State of Incorp.: L2
Type: 6-K | Act: 34 | File No.: 001-37569 | Film No.: 162076418
SIC: 2834 Pharmaceutical Preparations